Blockchain Registration Transaction Record

Helus Pharma CEO to Speak at TD Cowen Neuropsychiatry Summit

Helus Pharma CEO Michael Halstead to present at TD Cowen Neuropsychiatry Summit on Sept 23, 2026. Company advances novel serotonergic agonists for depression and anxiety.

The TD Cowen Novel Mechanisms in Neuropsychiatry Summit provides a prominent platform for Helus Pharma to showcase its novel serotonergic agonists (NSAs) to key opinion leaders, investors, and industry peers. As mental health disorders like depression and anxiety continue to rise globally, innovative treatments that target serotonin pathways and promote neuroplasticity could offer new hope for patients who have not responded to existing therapies. Helus Pharma's lead candidate, HLP003, has already received Breakthrough Therapy Designation from the FDA, underscoring its potential to address a significant unmet need. With HLP003 in Phase 3 and HLP004 in Phase 2, the company is at a critical juncture where investor and partner interest can accelerate development and eventual commercialization. This fireside chat not only raises awareness of Helus Pharma's pipeline but also highlights the broader shift toward psychedelic-inspired and serotonergic medicines in psychiatry. For patients and investors alike, the event signals progress in a field that could revolutionize mental health care and create substantial market opportunities.